Regeneron Pharmaceuticals, Inc.
REGNHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, Regeneron Pharmaceuticals, Inc. (REGN) is listed under Biotechnology. The company carries a $64.45B market cap, placing it firmly in the large-cap category. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Market Cap
$64.45B
Beta
0.30
P/E (TTM)
15.02
P/E (Fwd)
11.43
EPS (TTM)
$40.94
EPS (Fwd)
$53.77
ROE
14.5%
ROA
6.1%
Cash
$8.75B
Total Debt
$2.71B
Free CF
$3.27B
52W Change
25.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $8.75B in cash comfortably exceeding the $2.71B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $3.27B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 14.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $12.17B to $14.34B.
With a beta below 0.7, Regeneron Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing REGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.